Latest news
CORE Biomedicine Deepens Precision Oncology Pipeline With $21 Million Funding Round and Eisai Licensing Deal - tipranks.comtipranks.com · Sat, 01 Aug 2026 16:03:02 GMTOak Hill Bio merges with RA Capital SPAC; InnoCare’s TYK2 drug hits in Phase 3 - Endpoints NewsEndpoints News · Tue, 28 Jul 2026 07:00:00 GMT